# Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas

> **NCT03198026** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University** · enrollment: 30 (estimated)

## Conditions studied

- Non-Hodgkin's Lymphoma
- Ann Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
- Ann Arbor Stage II Follicular Lymphoma
- Ann Arbor Stage II Nodal Marginal Zone Lymphoma
- Ann Abor Stage III B-Cell Non-Hodgkin Lymphoma
- Ann Arbor Stage III Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
- Ann Arbor Stage III Follicular Lymphoma
- Ann Arbor Stage III Nodal Marginal Zone Lymphoma
- Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma
- Ann Arbor Stage IV Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
- Ann Arbor Stage IV Follicular Lymphoma
- Ann Arbor Stage IV Nodal Marginal Zone Lymphoma
- Grade 1 Follicular Lymphoma
- Grade 2 Follicular Lymphoma
- Grade 3a Follicular Lymphoma
- Indolent Non-hodgkin Lymphoma
- Stage II Splenic Marginal Zone Lymphoma
- Stage III Splenic Marginal Zone Lymphoma
- Stage IV Splenic Marginal Zone Lymphoma

## Interventions

- **DRUG:** Ibrutinib
- **BIOLOGICAL:** Obinutuzumab
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT03198026
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-02-20
- **Primary completion:** 2026-09-11
- **Final completion:** 2032-02-20
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-02-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03198026

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03198026, "Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03198026. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*